Join us at #EAACI2026 in Istanbul as we explore how the definition of disease control in hereditary angioedema \(HAE\) is evolving — and what this means for personalized patient management. At our CSL-sponsored symposium, an expert panel — including a patient with HAE who is also a physician managing the disease — will share perspectives on advancing care and improving outcomes. 🗓️ Saturday, June 13, 2026 ⏰ 12:00–13:00 TRT We look forward to connecting with the HAE community and continuing the conversation on individualized approaches in HAE. For healthcare professionals only.
CSL Is Investigating Two Potential New Treatments for Sickle Cell Disease
Like to learn more about Our Impact? Click here to view or download the 2025 Impact Report → | Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report → | CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
9 Jun
8 Jun
Sustained advocacy, led by the World Federation of Hemophilia \(WFH\), has resulted in the unanimous approval of a World Health Organization resolution, recognizing hemophilia and bleeding disorders as a global health priority. Learn how this could improve care for patients around the world. https://lnkd.in/gNBF4EYV #WHO #WFH #PatientAdvocacy #hemophilia #bleedingdisorders #vonWillebrandDisease #globalhealth #CSL
8 Jun
Ever wondered about the invisible hero protecting you every second? Meet plasma – the clear, golden liquid comprising over half your blood. @[Deborah Ebert Long MD], Head of Medical Affairs at CSL, shares how plasma, particularly its immunoglobulins, acts as your immune system's elite guard. We're proud to unlock this extraordinary power to create plasma-derived therapies for those battling life-threatening diseases: https://bit.ly/4x5wwol #CSL #PlasmaDonation #PlasmaDerivedTherapies
5 Jun
Celebrating PRIDE at CSL reinforces our commitment to building high‑performing teams where people feel safe to contribute fully and authentically. Inclusive environments drive stronger collaboration, better decision‑making and sustained innovation. This year’s theme, “Connecting Us with Kindness,” directly supports our ambition to lead with trust, respect and accountability. By recognizing PRIDE, we strengthen engagement, retention and the collective performance that enables CSL to deliver for our patients. #CSL #PrideMonth #Pride #HappyPride
3 Jun
At CSL, great science doesn’t start with molecules. It starts with people. Today we’re launching a series of stories that bring to life the people, motivations and determination behind our research. Learn more about the people powering our science: https://lnkd.in/et-3RGzZ #CSL #PeoplePoweringScience
2 Jun
We’re committed to more than medicine — we’re committed to people. CSL teams work tirelessly to improve life for patients with chronic conditions like kidney disease, helping them live fuller, healthier lives. If you want a career where your skills make a real difference, join us and help shape the future of healthcare: csl.com/careers #CSL #CSLImpactReport #CSLCareers #PromisingFutures
1 Jun
Prof. Heimburger Award 2026: There’s still time to apply! CSL is pleased to announce that the application period for the Prof. Heimburger Award 2026 has been extended from the previous deadline of May 29, 2026, to June 26, 2026; 11:59pm CET! To apply, simply submit your application via the Prof. Heimburger Award website: https://lnkd.in/gwZp5wYt This year, three global research grants will be awarded to early-career specialists to advance research within the fields of acquired and inherited bleeding disorders. To be considered, applications must be received by June 26, 2026; 11:59pm CET. Please note that eligibility criteria apply. Full details, including how to apply, are available on the Prof. Heimburger Award website: https://lnkd.in/eACFyzgx #ProfHeimburgerAward #HematologyResearch #BleedingDisorders #EarlyCareerResearchers #CSL
27 May
What does a day at CSL look like? For our teams, it’s a balance of collaboration, focus and purpose-driven work – each moment contributing to something bigger. Take a look inside a typical day and see how our people are making an impact. Explore careers: csl.com/careers #PromisingFutures #CareersAtCSL #CSL
26 May
In this segment of #CSLAsks , Lisa Butler, President & CEO of the GBS\|CIDP Foundation International , sits down with @[Emma Hatcher, MPH], Director of U.S. Patient Advocacy at CSL, to break down what it’s like to have Chronic Inflammatory Demyelinating Polyneuropathy. Lisa explains that CIDP, an autoimmune disease affecting the peripheral nervous system, causes extreme weakness and profound fatigue. These unpredictable symptoms can disrupt daily life, turning routine activities into significant challenges for those living with the condition. https://bit.ly/4f0Q070 #RareDisease #PatientAdvocacy #CSL #CIDP
22 May
What turns a "good deal" into a great partnership? CSL Leaders Hervé Gisserot , VarmX and Kurma Partners shared their view on what it takes to create the Next Generation of #Partnerships at this year's #SwissBiotechDay .